Prostate Cancer Clinical Masterclass Series

Welcome to this bonus episode in the Prostate Cancer Clinical Masterclass Series. This is an independent educational initiative organised by The Clinical Comms Group. In today’s episode our co-chiars, Sumit Subudhi and Gerhardt Attard, will summarise some of the opportunities and challenges they believe will be important in the next 1 to 2 years for prostate cancer treatment.

This month we are joined by Dr Joshua Lang, from the University of Wisconsin Carbone Comprehensive Cancer Center, Madison, who will present on the very current topic of ‘Metastatic Niche and Treatment Resistanc’. We will also hear from Prof Andrea Alimonti, from the Institute of Oncology Research, Bellinzona, who will help to add clarity around the fascinating topic of ‘Role of Microbiome in Treatment Resistance’. It is co-chaired by Dr Gerhardt Attard, from University College London, who leads the group disucssion to close the episode.

This month we are joined by Dr Lorelei Mucci, from the Harvard School of Public Health, Massachusetts, who will present on the very current topic of ‘Disparities in Ethnic Minorities’. We will also hear from Prof Derek Rosario, from Sheffield Teaching Hospitals, Sheffield, who will help to add clarity around the very current question of ‘Is There a Role for Diet and Exercise?’. It is co-chaired by Dr Gerhardt Attard, from University College London, U.K., who leads the group disucssion to close the episode.

This month we are joined by Prof Stacy Loeb, from NYU Langone Health and the Manhattan Veterans Affairs, who presents on 'Sleep Dysfunction in Prostate Cancer'. We will also hear from Prof Silke Gillessen, from the USI and the IOSI in Switzerland, who will present updates on the topic 'Tumour Metabolism as a Driver and Treatment Target'. It is co-chaired by Dr Sumit Subudhi, from MD Anderson Cancer Center, Houston, Texas, who leads the group disucssion to close the episode.

This month we are joined by Dr Osama Mohamad, from University of California, San Francisco, who will help to add clarity around the very current question of ‘Will Artificial Intelligence Ever Substitute for Pathologists?’. We will also hear from Prof Alicia Morgans, from Dana-Farber Cancer Institute, Massachusetts, who will present her thoughts on the topic of 'Strategies for Survivorship’. It is co-chaired by Dr Gerhardt Attard, from University College London, U.K., who leads the group disucssion to close the episode.

This month we are joined by Prof Samuel Denmeade, from the Johns Hopkins University School of Medicine, who gives a fascinating overview on research into 'Bipolar Testosterone Therapy'. This episode is co-chaired by Dr Sumit Subudhi, from MD Anderson Cancer Center, Houston, Texas, who leads the disucssion to close the episode.

This month we are joined by Dr Russell Pachynski, from Washington University, St Louis, who answers 'Do Bispecific Immunotherapies Have a Future?'. We will also hear from Prof Ana Aparicio, from MD Anderson Cancer Center, Houston, Texas, who will present her thoughts on the question 'What are Promising Treatment Approaches for Aggressive Variant / Neuroendocrine Prostate Cancer?'. It is co-chaired by Dr Sumit Subudhi, from MD Anderson Cancer Center, Houston, Texas, who leads the group disucssion to close the episode.

Join our co-chair, Gert Attard, as he offers summaries on the 4 biggest questions to come out of the 2023 ASCO GU conference. This is a bonus episode and we would love to hear your thougths and feedback if this type of content is valuable to you. Please let us know by leaving a comment on the episode video via the platform.

This month we are joined by Dr Vivek Narayan who is assistant Professor of medicine at the Abramson Cancer Center, University of Pennsylvania, who discusses What Limits the Efficacy of CAR-T Cell Therapies for Advanced Prostate Cancer. We also hear from our co-chair, Dr Sumit Subudhi, from MD Anderson Cancer Center, Texas, who will present on The Path Forward for Immune Checkpoint Therapies. Dr Subudhi also co-chairs the session and leads the disucssion to close the episode.

This month we are joined by Dr Emmanuel Antonarakis, from The University of Minnesota, USA, who discusses the exciting topic of B7-H3 as a New Drug Target in Prostate Cancer. This month is co-chaired by Dr Gert Attard, from The University College London, who leads the question-led disucssion to close the episode.

This month we are joined by Dr Mary-Ellen Taplin, from Dana Farber Cancer Institute,  USA, who discusses Neo-adjuvant Therapies for Prostate Cancer. We will also hear from Prof Janet Brown, from The University of Sheffield, U.K., who will present on Bone Protection in Prostate Cancer. It is co-chaired by Dr Sumit Subudhi, from MD Anderson Cancer Center, who leads the group disucssion to close the episode.

This month we are joined by Prof Ros Eeles, from The Institute of Cancer Research, U.K., who discusses Germline Testing Families of Prostate Cancer Patients. We will also hear from Dr Joaquin Mateo, from Val d'Hebron, Barcelona, Spain, who will present on Targeting Homologous Recombination Repair Deficiency. It is co-chaired by Dr Gerhardt Attard, from University College London, U.K., who leads the group disucssion to close the episode.

This month we are joined by Prof Michael Hofman, from PeterMac in Melbourne, Austrialia, who discusses Theranostics in Prostate Cancer. We will also hear from Dr Veeru Kasivisvanathan, from University College London, U.K., who will present on Best Use of MRI for Prostate Cancer Diagnosis. It is co-chaired by Dr Gerhardt Attard, from University College London, U.K., who leads the group disucssion to close the episode.

This month we are joined by Dr Daniel Spratt, from University Hospitals Seidman Cancer Center/ Case Western Reserve University, who discusses Molecular Classifiers for Treatment Rationalisation of Localised Disease. We will also hear from Prof Bertrand Tombal, from Université catholique de Louvain, Louvain-la-Neuve, who will present on LHRH Antagonists vs Agonists. It is co-chaired by Dr Sumit Subudhi, from MD Anderson Cancer Center, who leads the group disucssion to close the episode.